IMS: review of Chinese hospital medicine market in the third quarter of 2016

Source: Ames 2017-01-09 according to statistics, the total sales volume * of China's hospital pharmaceutical market in the third quarter of 2016 reached 179 billion yuan (data source: IMS China Hospital Pharmaceutical statistics report, > = 100 beds), an increase of 5.7% compared with the same period last year Based on the 12-month mat (rolling full year data *), the mat growth rate in the third quarter of 2016 was 6.4%, 0.2 percentage points higher than that in the second quarter of 2016 *Sales: purchase amount of Hospital Pharmacy * mat (rolling annual data): the total data of 12 months from the specified time node, which refers to the sales from the fourth quarter of 2015 to the third quarter of 2016 The new round of centralized drug bidding and purchase, which has attracted much attention, is currently only implemented in 7 provinces The impact of price reduction may not gradually appear until 2017-2018, and the actual price reduction pressure reflected in 2016 is not large In June, the national health and Family Planning Commission put forward the goal of cost control, striving to reduce the growth rate of national medical expenses to less than 10% by the end of 2017; in July, many places restricted or completely cancelled the outpatient intravenous antibiotics How the market changes in 2016 remains to be seen The market performance of multinational enterprises and domestic enterprises shows that the year-on-year growth rate of mat sales of multinational enterprises and domestic enterprises in the third quarter of 2016 is quite different The growth rate of multinational enterprises in this quarter is 7.6% higher than that in the same period of 2015, while that of domestic enterprises is 6.1% lower than that in the same period of 2015 According to the company's quarterly sales ranking, Pfizer, AstraZeneca and Shandong Qilu continue to occupy the top three positions, and Pfizer and AstraZeneca both showed double-digit mat growth this quarter From the city level, the competition pattern of multinational enterprises and domestic enterprises is changing: the growth rate of domestic enterprises in first tier cities is higher than that of multinational enterprises, and the growth rate of mat is 10.3% and 6.3% respectively; the growth rate of multinational enterprises in small and medium-sized cities is higher than that of domestic enterprises, and the growth rate of mat is 11.8% and 5.8% respectively First tier cities: Beijing, Shanghai, Guangzhou second tier cities: Chengdu, Shenyang, Chongqing, Tianjin, Nanjing, Hangzhou, Shenzhen, Jinan, Zhengzhou, Wuhan, Ningbo, Harbin, Suzhou, Xi'an, Changsha third tier cities: Changzhou, Taiyuan, Dalian, Qingdao, Urumqi, Wuxi, Changchun, Shijiazhuang, Guiyang, Kunming, Shaoxing, Wenzhou, Taizhou, Jinhua, Jiaxing, Yantai, Nantong, Yangzhou, Xuzhou, Nanyang key treatment areas and market performance of major products in terms of major treatment areas, tumor drugs, diabetes drugs, hypertension drugs and The growth of antithrombotic drugs is still rebounding However, the growth of intravenous solution products, antibiotics, proprietary Chinese medicine and auxiliary drugs continued to slow down due to multiple policy controls From the perspective of products, according to the product sales ranking in the third quarter of 2016, the products of multinational enterprises, Plavix and Lipitor, rose one place respectively from the previous quarter, becoming the champion and runner up products, while the products of domestic enterprises, Shenjie, dropped to the third place Domestic enterprise product dizosin rose to the fourth place with a strong year-on-year growth rate of 31.8% In this quarter, another multinational product, Shupu Shenzhen, entered the top ten list, ranking 10th The growth rate of other individual products only slightly changed, and the ranking did not fluctuate greatly.